339 related articles for article (PubMed ID: 20938767)
1. Early changes in biochemical markers of bone turnover and their relationship with bone mineral density changes after 24 months of treatment with teriparatide.
Blumsohn A; Marin F; Nickelsen T; Brixen K; Sigurdsson G; González de la Vera J; Boonen S; Liu-Léage S; Barker C; Eastell R;
Osteoporos Int; 2011 Jun; 22(6):1935-46. PubMed ID: 20938767
[TBL] [Abstract][Full Text] [Related]
2. Effect of Teriparatide Treatment on Circulating Periostin and Its Relationship to Regulators of Bone Formation and BMD in Postmenopausal Women With Osteoporosis.
Gossiel F; Scott JR; Paggiosi MA; Naylor KE; McCloskey EV; Peel NFA; Walsh JS; Eastell R
J Clin Endocrinol Metab; 2018 Apr; 103(4):1302-1309. PubMed ID: 29365099
[TBL] [Abstract][Full Text] [Related]
3. Early changes in biochemical markers of bone formation predict BMD response to teriparatide in postmenopausal women with osteoporosis.
Chen P; Satterwhite JH; Licata AA; Lewiecki EM; Sipos AA; Misurski DM; Wagman RB
J Bone Miner Res; 2005 Jun; 20(6):962-70. PubMed ID: 15883636
[TBL] [Abstract][Full Text] [Related]
4. Bone turnover markers to explain changes in lumbar spine BMD with abaloparatide and teriparatide: results from ACTIVE.
Eastell R; Mitlak BH; Wang Y; Hu M; Fitzpatrick LA; Black DM
Osteoporos Int; 2019 Mar; 30(3):667-673. PubMed ID: 30635696
[TBL] [Abstract][Full Text] [Related]
5. An algorithm using the early changes in PINP to predict the future BMD response for patients treated with daily teriparatide.
Niimi R; Kono T; Nishihara A; Hasegawa M; Matsumine A; Nakamura T; Kono T; Sudo A
Osteoporos Int; 2014 Jan; 25(1):377-84. PubMed ID: 23812597
[TBL] [Abstract][Full Text] [Related]
6. Early changes in biochemical markers of bone formation during teriparatide therapy correlate with improvements in vertebral strength in men with glucocorticoid-induced osteoporosis.
Farahmand P; Marin F; Hawkins F; Möricke R; Ringe JD; Glüer CC; Papaioannou N; Minisola S; Martínez G; Nolla JM; Niedhart C; Guañabens N; Nuti R; Martín-Mola E; Thomasius F; Peña J; Graeff C; Kapetanos G; Petto H; Gentzel A; Reisinger A; Zysset PK
Osteoporos Int; 2013 Dec; 24(12):2971-81. PubMed ID: 23740422
[TBL] [Abstract][Full Text] [Related]
7. Analysis of daily teriparatide treatment for osteoporosis in men.
Niimi R; Kono T; Nishihara A; Hasegawa M; Matsumine A; Kono T; Sudo A
Osteoporos Int; 2015 Apr; 26(4):1303-9. PubMed ID: 25567777
[TBL] [Abstract][Full Text] [Related]
8. Effects of previous antiresorptive therapy on the bone mineral density response to two years of teriparatide treatment in postmenopausal women with osteoporosis.
Boonen S; Marin F; Obermayer-Pietsch B; Simões ME; Barker C; Glass EV; Hadji P; Lyritis G; Oertel H; Nickelsen T; McCloskey EV;
J Clin Endocrinol Metab; 2008 Mar; 93(3):852-60. PubMed ID: 18160462
[TBL] [Abstract][Full Text] [Related]
9. Effects of morning vs. evening teriparatide injection on bone mineral density and bone turnover markers in postmenopausal osteoporosis.
Michalska D; Luchavova M; Zikan V; Raska I; Kubena AA; Stepan JJ
Osteoporos Int; 2012 Dec; 23(12):2885-91. PubMed ID: 22426952
[TBL] [Abstract][Full Text] [Related]
10. Correlations between biochemical markers of bone turnover and bone density responses in patients with glucocorticoid-induced osteoporosis treated with teriparatide or alendronate.
Burshell AL; Möricke R; Correa-Rotter R; Chen P; Warner MR; Dalsky GP; Taylor KA; Krege JH
Bone; 2010 Apr; 46(4):935-9. PubMed ID: 20060081
[TBL] [Abstract][Full Text] [Related]
11. Comparison of the effect of 18-month daily teriparatide administration on patients with rheumatoid arthritis and postmenopausal osteoporosis patients.
Ebina K; Hashimoto J; Shi K; Kashii M; Hirao M; Yoshikawa H
Osteoporos Int; 2014 Dec; 25(12):2755-65. PubMed ID: 25082556
[TBL] [Abstract][Full Text] [Related]
12. Usefulness of daily teriparatide treatment in elderly patients over 80 years of age.
Niimi R; Kono T; Nishihara A; Hasegawa M; Matsumine A; Kono T; Sudo A
Osteoporos Int; 2016 May; 27(5):1869-74. PubMed ID: 26759334
[TBL] [Abstract][Full Text] [Related]
13. Histomorphometric changes by teriparatide in alendronate-pretreated women with osteoporosis.
Stepan JJ; Burr DB; Li J; Ma YL; Petto H; Sipos A; Dobnig H; Fahrleitner-Pammer A; Michalská D; Pavo I
Osteoporos Int; 2010 Dec; 21(12):2027-36. PubMed ID: 20135094
[TBL] [Abstract][Full Text] [Related]
14. Effect of teriparatide on bone mineral density and biochemical markers in Japanese women with postmenopausal osteoporosis: a 6-month dose-response study.
Miyauchi A; Matsumoto T; Shigeta H; Tsujimoto M; Thiebaud D; Nakamura T
J Bone Miner Metab; 2008; 26(6):624-34. PubMed ID: 18979163
[TBL] [Abstract][Full Text] [Related]
15. Baseline serum PINP level is associated with the increase in hip bone mineral density seen with Romosozumab treatment in previously untreated women with osteoporosis.
Kashii M; Kamatani T; Nagayama Y; Miyama A; Tsuboi H; Ebina K
Osteoporos Int; 2023 Mar; 34(3):563-572. PubMed ID: 36585509
[TBL] [Abstract][Full Text] [Related]
16. PINP as a biological response marker during teriparatide treatment for osteoporosis.
Krege JH; Lane NE; Harris JM; Miller PD
Osteoporos Int; 2014 Sep; 25(9):2159-71. PubMed ID: 24599274
[TBL] [Abstract][Full Text] [Related]
17. Differential effects of teriparatide on BMD after treatment with raloxifene or alendronate.
Ettinger B; San Martin J; Crans G; Pavo I
J Bone Miner Res; 2004 May; 19(5):745-51. PubMed ID: 15068497
[TBL] [Abstract][Full Text] [Related]
18. Relationship between 3-month changes in biochemical markers of bone remodelling and changes in bone mineral density and fracture incidence in patients treated with strontium ranelate for 3 years.
Bruyère O; Collette J; Rizzoli R; Decock C; Ortolani S; Cormier C; Detilleux J; Reginster JY
Osteoporos Int; 2010 Jun; 21(6):1031-6. PubMed ID: 19813043
[TBL] [Abstract][Full Text] [Related]
19. Teriparatide's effects on quantitative ultrasound parameters and bone density in women with established osteoporosis.
Gonnelli S; Martini G; Caffarelli C; Salvadori S; Cadirni A; Montagnani A; Nuti R
Osteoporos Int; 2006 Oct; 17(10):1524-31. PubMed ID: 16767526
[TBL] [Abstract][Full Text] [Related]
20. Effects of intravenous zoledronic acid plus subcutaneous teriparatide [rhPTH(1-34)] in postmenopausal osteoporosis.
Cosman F; Eriksen EF; Recknor C; Miller PD; Guañabens N; Kasperk C; Papanastasiou P; Readie A; Rao H; Gasser JA; Bucci-Rechtweg C; Boonen S
J Bone Miner Res; 2011 Mar; 26(3):503-11. PubMed ID: 20814967
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]